Skip to content

Efficacy of platelet-rich fibrin (PRF) mixed demineralised tooth matrix (DTM) on periodontal status of 2nd molar following 3rd mo-lar surgery: A split-mouth controlled clinical trial.

Efficacy of platelet-rich fibrin (PRF) mixed demineralised tooth matrix (DTM) on periodontal status of 2nd molar following 3rd mo-lar surgery: A split-mouth controlled clinical trial.

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20240610006
Enrollment
14
Registered
2024-06-10
Start date
2020-08-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal defect at the distal aspect of lower 2nd molar after the surgical removal of the adjacent impacted 3rd molar. demineralised tooth matrix DTM periodontal healing platelet-rich fibrin PRF third molar removal

Interventions

Insert PRF into the lower 3rd molar extraction socket.,Insert the combination of PRF and DTM into the lower 3rd molar extraction socket.
Active Comparator Procedure/Surgery,Experimental Procedure/Surgery
PRF,PRF+DTM

Sponsors

Faculty of Dentistry, Prince of Songkhla University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Healthy patients aged between 20 and 40 years, with both lower third molars requiring surgical extraction, were eligible for inclusion in the study. These third molars must exhibit similar radiographic position and angulation, either mesioangular or horizontal, without any signs of pericoronitis in the two weeks preceding the surgery. Additionally, participants were required to present with at least 5mm distal defects of the adjacent second molar, measured from the cementoenamel junction (CEJ) to the crestal bone, as observed in the preoperative orthopantomogram (OPG).

Exclusion criteria

Exclusion criteria: Patients undergoing immunosuppressive treatment or systemic corticosteroid therapy, those with uncontrolled systemic diseases, pregnant or breast-feeding women, as well as those planning a pregnancy during the clinical trial period.

Design outcomes

Primary

MeasureTime frame
Probing depth (PD) 0, 3, 6, 9 months Clinical sulcular probing from gingival margin to pocket base

Secondary

MeasureTime frame
Clinical attachment loss (CAL) 0, 3, 6, 9 months Clinical probing from Cemento-enamel junnction to socket base,Crestal bone level (CBL) 0, 3, 6, 9 months Radiographic measurement from Cemento-enamel junction to prestal bone peak

Countries

Thailand

Contacts

Public ContactSrisurang Suttapreyasri

Faculty of Dentistry, Prince of Songkla University

srisurang.s@psu.ac.th074287591

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026